Quotient to ‘stretch’ core CDMO business with new PE owners

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Martin Barraud)
(Image: Getty/Martin Barraud)

Related tags: Quotient Sciences, CDMO, Private equity

Quotient Sciences has found new owners in the UK-based PE firm, Permira, as the CDMO eyes new opportunities to expand its business into adjacent service sectors and new geographies, says CEO.

The private equity (PE) firm Permira has signed a definitive agreement to acquire a majority stake in Quotient Sciences from companies controlled by GHO Capital and other investors.

The deal – financial terms of which were not disclosed – will support facility expansion, the addition of new hires, investment in capital equipment, expansion of service offerings, and more, said Quotient CEO Mark Egerton.

The contract development and manufacturing organization (CDMO) had been working with GHO Capital since 2015.

“We remain focused on building the next generation CDMO service business that is more attuned to addressing customer need in today’s rapidly evolving marketplace,”​ said Egerton, who will continue to lead the company with the current management team.

Market opportunity to grow the company’s Translational Pharmaceutics platform will drive organic growth, Egerton told us.

“In addition, a number of opportunities to stretch our core business into adjacent service sectors and additional geographies have also been identified – which form the basis of our inorganic growth plan,”​ he added.

The company has made several acquisitions over the last few years, among other milestones, including the launch of its US-based operations.

“Based upon this success, our aspirations to accelerate the growth of our business have also grown,” ​said Egerton, speaking to the acquisition. “We wanted to partner with a new PE firm that shared those aspirations and had the required capital resources to support an inorganic acquisition component of our business plan.”

Related news

Show more

Related products

show more

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Innovations in OSD

Innovations in OSD

Recorded the 06-Oct-2020 | Webinar

This DFE series of educational webinars looks at innovations in Oral Solid Dose Forms with the emergence of advanced technologies such as Continuous Manufacturing...

Register for free

Related suppliers

Follow us


View more